{
  "source": "PA-Notification-Cibinqo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1382-4\nProgram Prior Authorization/Notification\nMedication Cibinqo™ (abrocitinib) tablets\nP&T Approval Date 3/2022, 3/2023, 3/2024, 4/2025\nEffective Date 5/16/2025\n1. Background:\nCibinqo is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric\npatients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose\ndisease is not adequately controlled with other systemic drug products, including biologics, or\nwhen use of those therapies is inadvisable.\nLimitation of Use:\nCibinqo is not recommended in combination with other JAK inhibitors, biologic\nimmunomodulators, or with other immunosuppressants.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Cibinqo will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one systemic drug\nproduct for the treatment of atopic dermatitis\n-AND-\n(3) Patient is not receiving Cibinqo in combination with any of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Olumiant (baricitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\n(c) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Cibinqo will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cibinqo therapy\n-AND-\n(2) Patient is not receiving Cibinqo in combination with any of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto)]\n(b) Jan",
    "Cibinqo in combination with any of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Olumiant (baricitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\n(c) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Cibinqo [package insert]. New York, NY: Pfizer Inc.; December 2023.\nProgram Prior Authorization/Notification – Cibinqo (abrocitinib)\nChange Control\n3/2022 New program\n3/2023 Annual review. Updated background and criteria to reflect expanded\nindication for patients 12 years of age and older. Updated reference.\nAdded state mandate footnote.\n3/2024 Annual review. Removed age requirement from criteria. Updated\nreference.\n4/2025 Annual review with no changes to coverage criteria. Updated examples\nwith no change to clinical intent.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}